WS #17036
Holding: newest synthesis is 2d 9h old
Moderna reported a Q3 EPS of $0.38 versus a -$1.28 estimate, reversing a prior loss, and raised its 2026 revenue outlook by 6% to 16% above estimates. This strong performance highlights the resilience of biotech firms with diversified pipelines, offering a counter-narrative to the broader tech selloff driven by rate fears.
Biotech Earnings Beat
Moderna reported a Q3 EPS of $0.38 versus a -$1.28 estimate, reversing a prior loss, and raised its 2026 revenue outlook by 6% to 16% above estimates. This strong performance highlights the resilience of biotech firms with diversified pipelines, offering a counter-narrative to the broader tech selloff driven by rate fears.